Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 2, 2020

View Archived Issues

In T cells, exhaustion starts young

Antiviral protein produces flu mRNAs

Innovent opens phase I study in China with IBI-112 for autoimmune diseases

Additional interim results presented from proof-of-concept study of OTL-203 for MPS-I

Tohoku University divulges dioxolan derivatives for renal diseases

Novartis AG patents IKZF2 degradation inducers

Harvard College and Seoul National University disclose compounds for autoimmune disorders

PTC Therapeutics synthesizes new compounds for familial dysautonomia

Merck & Co. identifies new orexin receptor agonists

Preclinical and phase I data presented for GSK-3640254

Olfactory cells have unique response to flu virus

First clinical data for TAFIa inhibitor S-62798 presented

AM-535 demonstrates efficacy in model of diet-induced hyperammonemia

Elixirgen's COVID-19 vaccine candidate EXG-5003 set to enter phase I/II trials

Bristol-Myers Squibb reports phase I data for the antithrombotic milvexian

FDA approves Onureg for continued treatment of AML in first remission

Biotest completes phase III study of IgG Next Generation for primary immunodeficiency disease

Herantis' phase I/II study of CDNF for Parkinson's meets primary endpoint of safety and tolerability

Single domain antibody mimic receptors used to generate EGFR-HER2 bispecific CAR T cells

Atossa advances phase I study of AT-301 nasal spray for COVID-19

Arena begins phase II trial of etrasimod for moderate to severe alopecia areata

New phase III trial explores felbinac trometamol for postoperative pain in China

FDA approves Sogroya for adult growth hormone deficiency

FDA accepts INmune's IND for phase II trial of Quellor for immune-mediated complications of COVID-19

Poxel opens phase II trial of PXL-065 for noncirrhotic biopsy-proven NASH

Noxopharm cleared to begin phase I study of Veyonda for COVID-19

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...